Lumiton Completes Pilot Clinical Trial for Smart Clothing that Improves Psoriasis and Alopecia with Light Emission
Background on the Emergence of Innovative Optical Clothing Technology
This clinical trial, led by a research team from the Wake Forest University School of Medicine, was conducted to evaluate the impact of clothing incorporating innovative light-emitting technology on the treatment of skin diseases. Lumiton, a private company, has developed a patented fiber that absorbs energy in the ultraviolet (UV) and visible light spectrum (350-600 nm) and emits beneficial red and near-infrared (NIR, 600-1000 nm) light, demonstrating a unique mechanism. Conventional phototherapy requires expensive specialized equipment and frequent hospital visits, which limits patient access to treatment. In contrast, Lumiton's technology can provide low-level light therapy (LLLT) simply by wearing everyday clothing, attracting attention in the industry.
Clinical Efficacy and Disease Improvement
The completed 12-week pilot clinical trial (NCT05391178) involved 14 patients with psoriasis, alopecia areata (AA), and polymorphous light eruption (PMLE). In patients with psoriasis, significant clinical improvement or stabilization was observed in redness, thickness, and scale in the affected areas. In patients with alopecia areata, positive results were achieved with improvements in the Severity of Alopecia Tool (SALT) score, a standard metric for evaluating the degree of hair loss. Furthermore, in patients with polymorphous light eruption, which occurs upon exposure to ultraviolet light, no cases of disease recurrence (flare) were observed during the clinical period, demonstrating that Lumiton fibers perfectly perform the dual functions of ultraviolet protection (UPF 50+) and therapeutic light emission.
Paradigm Shift in the Home Care Device Market
The global psoriasis treatment market is estimated at approximately $21.7 billion to $33.8 billion in 2025 and is expected to exceed $44 billion in 2030. The alopecia areata market is also projected to grow to a maximum of $14.6 billion by 2030. In this market, Lumiton's light-converting clothing has shown the potential to be a powerful non-invasive adjunctive therapy that can complement existing systemic drug treatments or in-office phototherapy, which are invasive, have potential side effects, and have time constraints. By enabling patients to continuously self-treat simply by wearing clothes in their daily lives, it is expected to significantly maximize treatment compliance and become an important turning point in expanding the home healthcare and medical wearables market.
Future Commercialization Challenges and Clinical Limitations
This study has yielded encouraging results in confirming the efficacy of light-emitting clothing, but it has limitations in statistical generalization because it is not a randomized controlled trial (RCT) with a large patient population. The clinical study was a small pilot study with only 14 participants, and it was conducted as an adjunctive study in which patients continued to use existing topical or systemic treatments. Therefore, additional research is necessary to determine its efficacy as a stand-alone treatment. In the future, in order for Lumiton to move beyond a simple wellness clothing brand and obtain formal medical device approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), the top priority should be to secure objective data through a large-scale, placebo-controlled clinical trial.
This study demonstrates the commercial value of non-invasive home care solutions in the global psoriasis treatment market, which is estimated at $21.7 billion to $33.8 billion in 2025, and the alopecia areata market, which is expected to grow to $14.6 billion by 2030. This is the first pilot clinical study. From an investor's perspective, the development of high-functional clothing technology (Lumiton) has created a new wellness and adjunctive therapy category, which can be seen as a long-term portfolio diversification opportunity in the context of existing hardware-centric competition, such as Joovv and HairMax, which are in-office phototherapy devices and hair loss treatment devices. From the perspective of researchers and the medical community, the mechanism of absorbing ultraviolet light and converting it into therapeutic red and near-infrared light (600-1000 nm) expands the in vivo evidence that leads to pathological improvements such as T-cell apoptosis and collagen synthesis induction. In the medium to long term, if this technology does not remain limited to wellness wearables and obtains medical device approval from regulatory agencies (FDA/EMA) through a large-scale randomized controlled trial (RCT), it will become a driving force in leading the digital healthcare and prescription apparel market as a standard adjunctive therapy that maximizes patient convenience.
Source: ClinicalTrials.gov (api_ct)